NCT06420258 Deeper Intubation Make Effects on Cervical Esophageal ESD
| NCT ID | NCT06420258 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Fujian Provincial Hospital |
| Condition | Carcinoma in Situ of Cervical Part of Esophagus |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 40 participants in total. It began in 2022-10-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To compare the efficacy and safety of intratracheal deep intubation with traditional intubation in endoscopic submucosal dissection for early esophageal cancer in the cervical esophagus, and to follow up and assess their short-term clinical outcomes.
Eligibility Criteria
Inclusion Criteria: 1. The lesions mainly involve superficial esophageal squamous cell carcinoma or high-grade intraepithelial neoplasia (HGIN) in the cervical esophagus; 2. There is no evidence of regional lymph node or distant metastasis on endoscopic ultrasound (EUS) or CT/MRI imaging; 3. Participants have a thorough understanding of this study and voluntarily sign the informed consent form. Exclusion Criteria: * 1\. Patients who have received radiotherapy or chemotherapy before endoscopic submucosal dissection surgery; 2. Patients with severe comorbidities who are not suitable for endoscopic submucosal dissection surgery.
Contact & Investigator
Wei Liang, MD
STUDY DIRECTOR
Fujian Provintial Hospital
Frequently Asked Questions
Who can join the NCT06420258 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Carcinoma in Situ of Cervical Part of Esophagus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06420258 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06420258 currently recruiting?
Yes, NCT06420258 is actively recruiting participants. Contact the research team at 454202013@qq.com for enrollment information.
Where is the NCT06420258 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT06420258 clinical trial?
NCT06420258 is sponsored by Fujian Provincial Hospital. The principal investigator is Wei Liang, MD at Fujian Provintial Hospital. The trial plans to enroll 40 participants.